期刊
GLIA
卷 59, 期 8, 页码 1200-1204出版社
WILEY-BLACKWELL
DOI: 10.1002/glia.21130
关键词
isocitrate dehydrogenase; glioma; brain; glioblastoma; mutation
资金
- German Glioma Network (Deutsche Krebshilfe) [70-3163-Wi 3]
Isocitrate dehydrogenases (IDHs) convert isocitrate to alpha-ketoglutarate by oxidative decarboxylation and are thereby involved in multiple metabolic processes. Mutations in the genes encoding IDH1 and IDH2 were first reported in human gliomas in 2008 and later on also identified in a minority of patients with acute myeloid leukemia. The mutations universally affect codons 132 in IDH1 and 172 in IDH2 and result in decreased enzymatic activity. The oncogenic pathway triggered by IDH mutations may involve the activation of hypoxia-inducible factor pathway as well as the acquisition of a novel (gain of enzymatic) function consuming NADPH and generating alpha-hydroxyglutarate. Most intriguingly, IDH mutations are observed in similar to 70-80% of grade II/III gliomas and the majority of secondary glioblastomas, but only 10% of primary glioblastomas, suggesting a different cellular origin of the gliomas, which had previously been viewed as a multistep process of malignant progression. Understanding the oncogenic pathway mediated by mutant IDH might result in the development of novel, tailored pharmacological therapies for human glioma patients. (C) 2011 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据